HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry.

AbstractBackground:
Calcific uraemic arteriolopathy (CUA, calciphylaxis) is a rare disease predominantly in dialysis patients and associated with high mortality. Painful skin ulcerations and calcification of cutaneous arterioles characterize calciphylaxis.
Methods:
We established an observational, Internet-based registry allowing online notification for all German CUA cases. The registry recorded data about patient characteristics, biochemistry and therapies. Blood samples were stored in a central biobank.
Results:
Between 2006 and 2015, 253 CUA patients were recorded: median age 70 [interquartile range (IQR) 61-76] years, 60% females and 86% ( n = 207) dialysis patients, translating into an estimated annual incidence rate of 0.04% in German dialysis patients. Fifty-two per cent received vitamin K antagonists (VKAs) prior to CUA. Skin lesions were localized in 71% on the legs or gluteal region. In dialysis CUA patients median total serum calcium was 2.20 (IQR 2.06-2.37) mmol/L, phosphorus 1.67 (IQR 1.35-2.03) mmol/L, intact parathyroid hormone 147 (IQR 72-276) pg/mL and fetuin-A 0.21 (IQR 0.16-0.26) g/L (normal range 0.35-0.95). Median sclerostin, osteoprotegerin, TRAP5b, bone-specific alkaline phosphatase and c-terminal FGF23 levels were all elevated. The most frequently recorded therapeutic procedures in dialysis CUA patients were as follows: wound debridement (29% of cases), stopping VKA (25%), lowering calcium supply (24%), sodium thiosulphate (22%), application of vitamin K (18%), increase of dialysis duration/frequency (17%) and stoping active vitamin D (16%).
Conclusions:
Approximately 50% of CUA patients used VKA. Our data suggest that uncontrolled hyperparathyroidism is not the key determinant of calciphylaxis. Therapeutic strategies were heterogeneous. The experience of the German registry will help substantially to initiate a large-scale multinational CUA registry.
AuthorsVincent M Brandenburg, Rafael Kramann, Hansjörg Rothe, Nadine Kaesler, Joanna Korbiel, Paula Specht, Sophia Schmitz, Thilo Krüger, Jürgen Floege, Markus Ketteler
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (Nephrol Dial Transplant) Vol. 32 Issue 1 Pg. 126-132 (01 01 2017) ISSN: 1460-2385 [Electronic] England
PMID26908770 (Publication Type: Journal Article)
Copyright© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Chemical References
  • FGF23 protein, human
  • Vitamin K
  • Fibroblast Growth Factor-23
Topics
  • Aged
  • Calciphylaxis (diagnosis, drug therapy, etiology)
  • Female
  • Fibroblast Growth Factor-23
  • Humans
  • Kidney Failure, Chronic (therapy)
  • Male
  • Middle Aged
  • Registries (statistics & numerical data)
  • Renal Dialysis (adverse effects)
  • Vitamin K (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: